No. 22-628

Sanofi-Aventis U.S., LLC v. Mylan, Inc., et al.

Lower Court: Tenth Circuit
Docketed: 2023-01-09
Status: Denied
Type: Paid
Amici (1)Relisted (2) Experienced Counsel
Tags: antitrust antitrust-law distribution-channels exclusive-dealing market-competition market-foreclosure monopolization monopoly-power section-2 sherman-act
Key Terms:
Antitrust CriminalProcedure
Latest Conference: 2023-04-14 (distributed 2 times)
Question Presented (AI Summary)

When a monopolist's exclusionary conduct would foreclose equally (or potentially equally) efficient rivals from accessing significant channels of distribution, is the monopolist's conduct anticompetitive under § 2 of the Sherman Act?

Question Presented (OCR Extract)

QUESTION PRESENTED | This Court has held that when a firm “attempt[s] to , exclude rivals on some basis other than efficiency,” that | conduct is unlawfully exclusionary. Aspen Skiing Co. v. | Aspen Highlands Skiing Corp., 472 U.S. 585, 605 (1985) | (citation and quotation marks omitted). A number of | lower courts have applied this principle to monopoliza| tion claims based on exclusive dealing, holding that a mo| nopolist’s exclusive contracts are anticompetitive if they | “can exclude equally efficient (or potentially equally effi| cient) rivals.” ZF Meritor, LLC v. Eaton Corp., 696 F.3d | 254, 281 (3d Cir. 2012). | Respondents’ EpiPen held a monopoly in the market | for devices to treat a life-threatening allergy condition. , When Petitioner launched the first true rival to EpiPen, | Respondents used their +90% durable monopoly share to | threaten—and indeed punish—market participants for | even considering purchasing a competing product from ‘ Petitioner. Respondents’ penalties were sufficient to exclude competition regardless of the rival’s efficiency or price—the largest: dealer in the United States informed Petitioner that even a 100% discount would not be enough to access consumers. That evidence would have been material under the approach endorsed by Third, : Sixth, Eleventh, and D.C. Circuits. Yet, the Tenth Circuit refused to consider it. : The question presented is: When a monopolist’s exclusionary conduct would foreclose equally (or potentially equally) efficient rivals from accessing significant channels of distribution, is the monopolist’s conduct anticompetitive under § 2 of the Sherman Act? (ii)

Docket Entries

2023-04-17
Petition DENIED.
2023-03-22
DISTRIBUTED for Conference of 4/14/2023.
2023-03-21
2023-03-08
2023-02-08
2023-01-19
Motion to extend the time to file a response is granted and the time is extended to and including March 10, 2023.
2023-01-18
Motion to extend the time to file a response from February 8, 2023 to March 10, 2023, submitted to The Clerk.
2023-01-09
Motion (22M46) for leave to file a petition for a writ of certiorari with the supplemental appendix under seal Granted.
2022-12-07
MOTION (22M46) DISTRIBUTED for Conference of 1/6/2023.
2022-11-28
Motion (22M46) for leave to file a petition for a writ of certiorari with the supplemental appendix under seal filed.
2022-11-28
Petition for a writ of certiorari filed. (Response due February 8, 2023)
2022-10-18
Application (22A322) granted by Justice Gorsuch extending the time to file until November 28, 2022.
2022-10-18
Letter from Mylan Inc., et al. filed.
2022-10-14
Application (22A322) to extend the time to file a petition for a writ of certiorari from October 27, 2022 to December 23, 2022, submitted to Justice Gorsuch.

Attorneys

Allergy & Asthma Network
John David MooreSchlam Stone & Dolan LLP, Amicus
John David MooreSchlam Stone & Dolan LLP, Amicus
Mylan, Inc. and Mylan Specialty, LP
Steffen Nathanael JohnsonWilson Sonsini Goodrich & Rosati, Respondent
Steffen Nathanael JohnsonWilson Sonsini Goodrich & Rosati, Respondent
Sanofi-Aventis U.S., LLC
Gregory SilbertWeil Gotshal & Manges LLP, Petitioner
Gregory SilbertWeil Gotshal & Manges LLP, Petitioner